Sarcomatoid Renal Cell Carcinoma

• CLINICAL_TRIALS research · 2026-04-15
  Clinical Trial Update: Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma [Phase 1]

  Phase 1 clinical trial evaluating nivolumab and ipilimumab with and without Camu Camu in metastatic renal cell carcinoma, including clear ce…

• CLINICAL_TRIALS research · 2026-04-07
  Clinical Trial Update: A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma [Phase 1, Phase 2]

  A clinical trial update on AK104 plus axitinib in advanced/metastatic special pathological subtypes of renal cell carcinoma (Phase 1/Phase 2…

• CLINICAL_TRIALS research · 2026-03-05
  Clinical Trial Update: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer [Phase 1]

  Phase 1 trial evaluating CBM588 in combination with nivolumab and cabozantinib for advanced or metastatic renal cell carcinoma.

• CLINICAL_TRIALS research · 2026-02-27
  Clinical Trial Update: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer [Phase 1]

  Phase 1 clinical trial evaluating nivolumab and ipilimumab, with or without the EXL01 live biotherapeutic product, for metastatic renal cell…

• CLINICAL_TRIALS research · 2026-01-09
  Clinical Trial Update: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma [Phase 2]

  Phase 2 clinical trial evaluating cabozantinib or sunitinib malate in patients with metastatic variant histology renal cell carcinoma, inclu…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-10-20
  Clinical Trial Update: RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy [Phase 2]

  A Phase 2 clinical trial update evaluating RP2 in combination with tivozanib for metastatic renal cell carcinoma after progression on immuno…

• CLINICAL_TRIALS research · 2025-09-23
  Clinical Trial Update: Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery [Phase 2]

  Phase 2 trial exploring adding CBM588 to pembrolizumab for renal cell carcinoma after surgery; the study status is NOT_YET_RECRUITING.

• CLINICAL_TRIALS research · 2025-09-09
  Clinical Trial Update: Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial [Phase 1, Phase 2]

  Clinical trial update describing the ICON study, evaluating a combination of an inulin gel with ipilimumab and nivolumab for locally advance…

• CLINICAL_TRIALS research · 2025-06-12
  Clinical Trial Update: An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer [Phase 2]

  A Phase 2 trial update evaluating imaging approaches for post-operative staging in kidney cancer, comparing 89Zr-DFO-GmAb PET/CT to contrast…

• CLINICAL_TRIALS research · 2024-05-30
  Clinical Trial Update: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer [Phase 1]

  Phase 1 trial evaluating CBM588 capsules in combination with nivolumab and ipilimumab for advanced or metastatic renal cell carcinoma, inclu…